JP2007535297A5 - - Google Patents

Info

Publication number

JP2007535297A5

JP2007535297A5 JP2006517785A JP2006517785A JP2007535297A5 JP 2007535297 A5 JP2007535297 A5 JP 2007535297A5 JP 2006517785 A JP2006517785 A JP 2006517785A JP 2006517785 A JP2006517785 A JP 2006517785A JP 2007535297 A5 JP2007535297 A5 JP 2007535297A5

Authority

JP

Japan

Prior art keywords

polypeptide

domain

molecule

binding

composition

Prior art date

2004-06-28

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims description 483
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 398
• 230000027455 binding Effects 0.000 claims description 391
• 229920001184 polypeptide Polymers 0.000 claims description 385
• 239000000427 antigen Substances 0.000 claims description 141
• 108091007433 antigens Proteins 0.000 claims description 140
• 102000036639 antigens Human genes 0.000 claims description 140
• 210000004027 cell Anatomy 0.000 claims description 113
• 239000000203 mixture Substances 0.000 claims description 105
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 86
• 206010028980 Neoplasm Diseases 0.000 claims description 79
• 108010075254 C-Peptide Proteins 0.000 claims description 77
• 239000000539 dimer Substances 0.000 claims description 61
• 239000003446 ligand Substances 0.000 claims description 56
• 102000005962 receptors Human genes 0.000 claims description 55
• 108020003175 receptors Proteins 0.000 claims description 55
• 239000003814 drug Substances 0.000 claims description 44
• 238000011282 treatment Methods 0.000 claims description 44
• 150000007523 nucleic acids Chemical class 0.000 claims description 39
• 102000039446 nucleic acids Human genes 0.000 claims description 36
• 108020004707 nucleic acids Proteins 0.000 claims description 36
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 34
• 239000000651 prodrug Substances 0.000 claims description 33
• 229940002612 prodrug Drugs 0.000 claims description 33
• 239000013598 vector Substances 0.000 claims description 30
• 239000002773 nucleotide Substances 0.000 claims description 27
• 125000003729 nucleotide group Chemical group 0.000 claims description 27
• 230000015572 biosynthetic process Effects 0.000 claims description 23
• 201000011510 cancer Diseases 0.000 claims description 23
• 238000004519 manufacturing process Methods 0.000 claims description 22
• 210000004881 tumor cell Anatomy 0.000 claims description 20
• 230000003197 catalytic effect Effects 0.000 claims description 18
• 208000027866 inflammatory disease Diseases 0.000 claims description 17
• 230000008901 benefit Effects 0.000 claims description 14
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 13
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 13
• 238000003786 synthesis reaction Methods 0.000 claims description 13
• 208000023275 Autoimmune disease Diseases 0.000 claims description 11
• 206010025323 Lymphomas Diseases 0.000 claims description 11
• 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 8
• 101150029707 ERBB2 gene Proteins 0.000 claims description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 3
• 230000009870 specific binding Effects 0.000 claims description 2
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 150
• 238000000034 method Methods 0.000 description 127
• 108090000623 proteins and genes Proteins 0.000 description 95
• 108010029485 Protein Isoforms Proteins 0.000 description 61
• 102000001708 Protein Isoforms Human genes 0.000 description 61
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 60
• 102000004169 proteins and genes Human genes 0.000 description 54
• 235000001014 amino acid Nutrition 0.000 description 52
• 235000018102 proteins Nutrition 0.000 description 48
• 108060003951 Immunoglobulin Proteins 0.000 description 46
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 46
• 102000018358 immunoglobulin Human genes 0.000 description 46
• 108020001507 fusion proteins Proteins 0.000 description 42
• 102000037865 fusion proteins Human genes 0.000 description 42
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 36
• 239000000243 solution Substances 0.000 description 35
• 150000001413 amino acids Chemical class 0.000 description 33
• 108020004414 DNA Proteins 0.000 description 32
• 229940024606 amino acid Drugs 0.000 description 32
• 229940079593 drug Drugs 0.000 description 29
• 238000000746 purification Methods 0.000 description 28
• 208000035475 disorder Diseases 0.000 description 24
• 238000006467 substitution reaction Methods 0.000 description 24
• 229940127089 cytotoxic agent Drugs 0.000 description 23
• 201000010099 disease Diseases 0.000 description 22
• 230000001965 increasing effect Effects 0.000 description 22
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 21
• 239000012634 fragment Substances 0.000 description 21
• 231100000599 cytotoxic agent Toxicity 0.000 description 20
• 239000000463 material Substances 0.000 description 20
• 238000002360 preparation method Methods 0.000 description 20
• 239000002246 antineoplastic agent Substances 0.000 description 19
• 238000012217 deletion Methods 0.000 description 19
• 230000037430 deletion Effects 0.000 description 19
• 230000003993 interaction Effects 0.000 description 19
• 239000000178 monomer Substances 0.000 description 19
• 241000699666 Mus <mouse, genus> Species 0.000 description 18
• 239000002738 chelating agent Substances 0.000 description 18
• 230000001225 therapeutic effect Effects 0.000 description 18
• 125000000539 amino acid group Chemical group 0.000 description 17
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 17
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 17
• 235000011130 ammonium sulphate Nutrition 0.000 description 17
• 230000000694 effects Effects 0.000 description 17
• 230000004927 fusion Effects 0.000 description 17
• 150000003839 salts Chemical class 0.000 description 17
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 17
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 16
• 239000002619 cytotoxin Substances 0.000 description 16
• 239000000126 substance Substances 0.000 description 16
• 230000006870 function Effects 0.000 description 15
• 238000000926 separation method Methods 0.000 description 14
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 13
• 108091028043 Nucleic acid sequence Proteins 0.000 description 13
• 238000007792 addition Methods 0.000 description 13
• 210000004408 hybridoma Anatomy 0.000 description 13
• 230000002209 hydrophobic effect Effects 0.000 description 13
• 239000013612 plasmid Substances 0.000 description 13
• 230000002829 reductive effect Effects 0.000 description 13
• 210000001519 tissue Anatomy 0.000 description 13
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 12
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
• 230000001154 acute effect Effects 0.000 description 12
• -1 ammonium ions Chemical class 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 230000000295 complement effect Effects 0.000 description 12
• 239000013604 expression vector Substances 0.000 description 12
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
• 231100000765 toxin Toxicity 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
• 239000000872 buffer Substances 0.000 description 11
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 239000000499 gel Substances 0.000 description 11
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 11
• 238000002372 labelling Methods 0.000 description 11
• 230000004048 modification Effects 0.000 description 11
• 238000012986 modification Methods 0.000 description 11
• 229920000642 polymer Polymers 0.000 description 11
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 11
• 229960004618 prednisone Drugs 0.000 description 11
• 239000000047 product Substances 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 238000003860 storage Methods 0.000 description 11
• 208000011580 syndromic disease Diseases 0.000 description 11
• 238000002512 chemotherapy Methods 0.000 description 10
• 238000004587 chromatography analysis Methods 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 231100000433 cytotoxic Toxicity 0.000 description 10
• 230000001472 cytotoxic effect Effects 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• 239000001488 sodium phosphate Substances 0.000 description 10
• 229910000162 sodium phosphate Inorganic materials 0.000 description 10
• 101150047061 tag-72 gene Proteins 0.000 description 10
• 238000002560 therapeutic procedure Methods 0.000 description 10
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 10
• 108010006654 Bleomycin Proteins 0.000 description 9
• 102000004127 Cytokines Human genes 0.000 description 9
• 102000053602 DNA Human genes 0.000 description 9
• 102000009109 Fc receptors Human genes 0.000 description 9
• 108010087819 Fc receptors Proteins 0.000 description 9
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 9
• 108020004682 Single-Stranded DNA Proteins 0.000 description 9
• 229960001561 bleomycin Drugs 0.000 description 9
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 9
• 210000001185 bone marrow Anatomy 0.000 description 9
• 235000018417 cysteine Nutrition 0.000 description 9
• 239000012636 effector Substances 0.000 description 9
• 229960005420 etoposide Drugs 0.000 description 9
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 9
• 230000002163 immunogen Effects 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• 210000004698 lymphocyte Anatomy 0.000 description 9
• 229960000485 methotrexate Drugs 0.000 description 9
• 238000001542 size-exclusion chromatography Methods 0.000 description 9
• 230000008685 targeting Effects 0.000 description 9
• 239000003053 toxin Substances 0.000 description 9
• 108700012359 toxins Proteins 0.000 description 9
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 8
• 108090000695 Cytokines Proteins 0.000 description 8
• 101710112752 Cytotoxin Proteins 0.000 description 8
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 8
• 241000124008 Mammalia Species 0.000 description 8
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 8
• 210000001744 T-lymphocyte Anatomy 0.000 description 8
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
• 230000001363 autoimmune Effects 0.000 description 8
• 210000003719 b-lymphocyte Anatomy 0.000 description 8
• 230000037396 body weight Effects 0.000 description 8
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 230000036961 partial effect Effects 0.000 description 8
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 8
• 229960000624 procarbazine Drugs 0.000 description 8
• 230000000069 prophylactic effect Effects 0.000 description 8
• 230000005855 radiation Effects 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 241000894006 Bacteria Species 0.000 description 7
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 7
• 238000003384 imaging method Methods 0.000 description 7
• 230000005847 immunogenicity Effects 0.000 description 7
• 238000000338 in vitro Methods 0.000 description 7
• 230000003211 malignant effect Effects 0.000 description 7
• 239000003550 marker Substances 0.000 description 7
• 230000001613 neoplastic effect Effects 0.000 description 7
• 238000012216 screening Methods 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 239000002904 solvent Substances 0.000 description 7
• 239000000758 substrate Substances 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
• QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical group OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 6
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
• 229920002684 Sepharose Polymers 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 6
• 241000700605 Viruses Species 0.000 description 6
• 238000013459 approach Methods 0.000 description 6
• 230000004071 biological effect Effects 0.000 description 6
• 238000004113 cell culture Methods 0.000 description 6
• 230000001684 chronic effect Effects 0.000 description 6
• 238000002648 combination therapy Methods 0.000 description 6
• 239000002254 cytotoxic agent Substances 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 229960004679 doxorubicin Drugs 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 229940072221 immunoglobulins Drugs 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 230000004054 inflammatory process Effects 0.000 description 6
• 230000004807 localization Effects 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• 230000000813 microbial effect Effects 0.000 description 6
• 229920001223 polyethylene glycol Polymers 0.000 description 6
• 238000001959 radiotherapy Methods 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 229960004641 rituximab Drugs 0.000 description 6
• 239000002002 slurry Substances 0.000 description 6
• 238000007920 subcutaneous administration Methods 0.000 description 6
• 230000007704 transition Effects 0.000 description 6
• 229960003048 vinblastine Drugs 0.000 description 6
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 6
• 229960004528 vincristine Drugs 0.000 description 6
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 229920000936 Agarose Polymers 0.000 description 5
• 206010065553 Bone marrow failure Diseases 0.000 description 5
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 5
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 5
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
• 230000005526 G1 to G0 transition Effects 0.000 description 5
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 5
• 206010061218 Inflammation Diseases 0.000 description 5
• 102100029268 Neurotrophin-3 Human genes 0.000 description 5
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 5
• 230000002378 acidificating effect Effects 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 230000002494 anti-cea effect Effects 0.000 description 5
• 125000003118 aryl group Chemical group 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 239000010949 copper Substances 0.000 description 5
• 229960004397 cyclophosphamide Drugs 0.000 description 5
• 229960000684 cytarabine Drugs 0.000 description 5
• 239000000824 cytostatic agent Substances 0.000 description 5
• 238000000502 dialysis Methods 0.000 description 5
• 238000010828 elution Methods 0.000 description 5
• 229950003499 fibrin Drugs 0.000 description 5
• 230000036541 health Effects 0.000 description 5
• 239000000710 homodimer Substances 0.000 description 5
• 230000028993 immune response Effects 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 238000001990 intravenous administration Methods 0.000 description 5
• 238000004255 ion exchange chromatography Methods 0.000 description 5
• 210000000265 leukocyte Anatomy 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 244000005700 microbiome Species 0.000 description 5
• 210000005170 neoplastic cell Anatomy 0.000 description 5
• 231100000252 nontoxic Toxicity 0.000 description 5
• 230000003000 nontoxic effect Effects 0.000 description 5
• 230000008569 process Effects 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 230000028327 secretion Effects 0.000 description 5
• 238000010561 standard procedure Methods 0.000 description 5
• 229940124597 therapeutic agent Drugs 0.000 description 5
• 125000003396 thiol group Chemical group [H]S* 0.000 description 5
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 4
• 201000009030 Carcinoma Diseases 0.000 description 4
• 238000002965 ELISA Methods 0.000 description 4
• 102000006395 Globulins Human genes 0.000 description 4
• 108010044091 Globulins Proteins 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 239000004471 Glycine Substances 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 108010092694 L-Selectin Proteins 0.000 description 4
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
• 241001529936 Murinae Species 0.000 description 4
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
• 108010025020 Nerve Growth Factor Proteins 0.000 description 4
• 108090000099 Neurotrophin-4 Proteins 0.000 description 4
• 238000012408 PCR amplification Methods 0.000 description 4
• 241000721454 Pemphigus Species 0.000 description 4
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 238000012300 Sequence Analysis Methods 0.000 description 4
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
• 239000004473 Threonine Substances 0.000 description 4
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
• 235000004279 alanine Nutrition 0.000 description 4
• 125000000217 alkyl group Chemical group 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 230000006907 apoptotic process Effects 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 230000001588 bifunctional effect Effects 0.000 description 4
• 230000003196 chaotropic effect Effects 0.000 description 4
• 238000010367 cloning Methods 0.000 description 4
• 208000029742 colonic neoplasm Diseases 0.000 description 4
• 230000021615 conjugation Effects 0.000 description 4
• 238000010276 construction Methods 0.000 description 4
• 108010057085 cytokine receptors Proteins 0.000 description 4
• 238000013461 design Methods 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• 238000006471 dimerization reaction Methods 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 238000001962 electrophoresis Methods 0.000 description 4
• 230000008030 elimination Effects 0.000 description 4
• 238000003379 elimination reaction Methods 0.000 description 4
• 239000003797 essential amino acid Substances 0.000 description 4
• 235000020776 essential amino acid Nutrition 0.000 description 4
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
• 239000011672 folinic acid Substances 0.000 description 4
• 235000008191 folinic acid Nutrition 0.000 description 4
• 239000003102 growth factor Substances 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• 239000000833 heterodimer Substances 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• 229960001101 ifosfamide Drugs 0.000 description 4
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 4
• 230000001900 immune effect Effects 0.000 description 4
• 208000026278 immune system disease Diseases 0.000 description 4
• 238000003018 immunoassay Methods 0.000 description 4
• 229940127121 immunoconjugate Drugs 0.000 description 4
• 230000016784 immunoglobulin production Effects 0.000 description 4
• 238000010348 incorporation Methods 0.000 description 4
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
• 229960000310 isoleucine Drugs 0.000 description 4
• 229960001691 leucovorin Drugs 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• 238000002703 mutagenesis Methods 0.000 description 4
• 231100000350 mutagenesis Toxicity 0.000 description 4
• 201000000050 myeloid neoplasm Diseases 0.000 description 4
• 230000007935 neutral effect Effects 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 239000002245 particle Substances 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
• 102000040430 polynucleotide Human genes 0.000 description 4
• 108091033319 polynucleotide Proteins 0.000 description 4
• 239000002157 polynucleotide Substances 0.000 description 4
• 239000002243 precursor Substances 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 238000003127 radioimmunoassay Methods 0.000 description 4
• 230000000306 recurrent effect Effects 0.000 description 4
• 239000011347 resin Substances 0.000 description 4
• 229920005989 resin Polymers 0.000 description 4
• 108091008146 restriction endonucleases Proteins 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 239000004094 surface-active agent Substances 0.000 description 4
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
• 239000004474 valine Substances 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 3
• 208000003950 B-cell lymphoma Diseases 0.000 description 3
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
• 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
• 102000000844 Cell Surface Receptors Human genes 0.000 description 3
• 108010001857 Cell Surface Receptors Proteins 0.000 description 3
• 241000282693 Cercopithecidae Species 0.000 description 3
• 108010012236 Chemokines Proteins 0.000 description 3
• 102000019034 Chemokines Human genes 0.000 description 3
• 206010009944 Colon cancer Diseases 0.000 description 3
• 241000699802 Cricetulus griseus Species 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 102000001301 EGF receptor Human genes 0.000 description 3
• 108060006698 EGF receptor Proteins 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 108010073385 Fibrin Proteins 0.000 description 3
• 102000009123 Fibrin Human genes 0.000 description 3
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• 102000009465 Growth Factor Receptors Human genes 0.000 description 3
• 108010009202 Growth Factor Receptors Proteins 0.000 description 3
• 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
• 108010000521 Human Growth Hormone Proteins 0.000 description 3
• 102000002265 Human Growth Hormone Human genes 0.000 description 3
• 239000000854 Human Growth Hormone Substances 0.000 description 3
• 108010073807 IgG Receptors Proteins 0.000 description 3
• 102000015696 Interleukins Human genes 0.000 description 3
• 108010063738 Interleukins Proteins 0.000 description 3
• 208000011200 Kawasaki disease Diseases 0.000 description 3
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
• 102000016551 L-selectin Human genes 0.000 description 3
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 3
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
• 108090000742 Neurotrophin 3 Proteins 0.000 description 3
• 108010001014 Plasminogen Activators Proteins 0.000 description 3
• 102000001938 Plasminogen Activators Human genes 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 229920005654 Sephadex Polymers 0.000 description 3
• 239000012507 Sephadex™ Substances 0.000 description 3
• 101710120037 Toxin CcdB Proteins 0.000 description 3
• 101150117115 V gene Proteins 0.000 description 3
• MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 3
• 230000035508 accumulation Effects 0.000 description 3
• 238000009825 accumulation Methods 0.000 description 3
• 238000009098 adjuvant therapy Methods 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 238000001042 affinity chromatography Methods 0.000 description 3
• 230000002776 aggregation Effects 0.000 description 3
• 238000004220 aggregation Methods 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 239000003114 blood coagulation factor Substances 0.000 description 3
• 108010006025 bovine growth hormone Proteins 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• 150000001720 carbohydrates Chemical group 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 238000006555 catalytic reaction Methods 0.000 description 3
• 229960004630 chlorambucil Drugs 0.000 description 3
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 3
• 238000011210 chromatographic step Methods 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
• 229960004316 cisplatin Drugs 0.000 description 3
• 238000011109 contamination Methods 0.000 description 3
• 239000005289 controlled pore glass Substances 0.000 description 3
• 239000012228 culture supernatant Substances 0.000 description 3
• 102000003675 cytokine receptors Human genes 0.000 description 3
• 230000009089 cytolysis Effects 0.000 description 3
• 238000006731 degradation reaction Methods 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 229940088597 hormone Drugs 0.000 description 3
• 239000005556 hormone Substances 0.000 description 3
• 229960001001 ibritumomab tiuxetan Drugs 0.000 description 3
• 230000036039 immunity Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000001506 immunosuppresive effect Effects 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 229940047122 interleukins Drugs 0.000 description 3
• 238000001361 intraarterial administration Methods 0.000 description 3
• 238000007918 intramuscular administration Methods 0.000 description 3
• 230000005865 ionizing radiation Effects 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 208000032839 leukemia Diseases 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 229960002247 lomustine Drugs 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
• 229960004961 mechlorethamine Drugs 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 210000004379 membrane Anatomy 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 229960004857 mitomycin Drugs 0.000 description 3
• 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 3
• 201000006417 multiple sclerosis Diseases 0.000 description 3
• 230000009826 neoplastic cell growth Effects 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 229960003330 pentetic acid Drugs 0.000 description 3
• 239000008363 phosphate buffer Substances 0.000 description 3
• 229940127126 plasminogen activator Drugs 0.000 description 3
• 239000000843 powder Substances 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 210000001236 prokaryotic cell Anatomy 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 239000002534 radiation-sensitizing agent Substances 0.000 description 3
• 238000011363 radioimmunotherapy Methods 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 102220080600 rs797046116 Human genes 0.000 description 3
• 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 125000006850 spacer group Chemical group 0.000 description 3
• 235000000346 sugar Nutrition 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 231100000331 toxic Toxicity 0.000 description 3
• 230000002588 toxic effect Effects 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000009466 transformation Effects 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 241001515965 unidentified phage Species 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical class NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
• 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
• 102400001282 Atrial natriuretic peptide Human genes 0.000 description 2
• 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 2
• 102000004506 Blood Proteins Human genes 0.000 description 2
• 108010017384 Blood Proteins Proteins 0.000 description 2
• 206010051779 Bone marrow toxicity Diseases 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 2
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 102100024217 CAMPATH-1 antigen Human genes 0.000 description 2
• 108010041884 CD4 Immunoadhesins Proteins 0.000 description 2
• 102100032912 CD44 antigen Human genes 0.000 description 2
• 108010065524 CD52 Antigen Proteins 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 108020004705 Codon Proteins 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
• 206010010741 Conjunctivitis Diseases 0.000 description 2
• 208000011231 Crohn disease Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
• 102000016607 Diphtheria Toxin Human genes 0.000 description 2
• 108010053187 Diphtheria Toxin Proteins 0.000 description 2
• 206010015150 Erythema Diseases 0.000 description 2
• 102000003951 Erythropoietin Human genes 0.000 description 2
• 108090000394 Erythropoietin Proteins 0.000 description 2
• 229930189413 Esperamicin Natural products 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
• 241000233866 Fungi Species 0.000 description 2
• 208000005577 Gastroenteritis Diseases 0.000 description 2
• 208000007465 Giant cell arteritis Diseases 0.000 description 2
• 206010018364 Glomerulonephritis Diseases 0.000 description 2
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
• BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 2
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 2
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 206010062016 Immunosuppression Diseases 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
• 108010002386 Interleukin-3 Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 108010025815 Kanamycin Kinase Proteins 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
• 102000016267 Leptin Human genes 0.000 description 2
• 108010092277 Leptin Proteins 0.000 description 2
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
• 102000009151 Luteinizing Hormone Human genes 0.000 description 2
• 108010073521 Luteinizing Hormone Proteins 0.000 description 2
• 108010074338 Lymphokines Proteins 0.000 description 2
• 102000008072 Lymphokines Human genes 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
• 229930192392 Mitomycin Natural products 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 206010028851 Necrosis Diseases 0.000 description 2
• 102000015336 Nerve Growth Factor Human genes 0.000 description 2
• 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
• 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
• 102000003683 Neurotrophin-4 Human genes 0.000 description 2
• 102100033857 Neurotrophin-4 Human genes 0.000 description 2
• 108091093105 Nuclear DNA Proteins 0.000 description 2
• 206010030113 Oedema Diseases 0.000 description 2
• 108700026244 Open Reading Frames Proteins 0.000 description 2
• 101710160107 Outer membrane protein A Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 102000003982 Parathyroid hormone Human genes 0.000 description 2
• 108090000445 Parathyroid hormone Proteins 0.000 description 2
• 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 2
• 201000011152 Pemphigus Diseases 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 206010060862 Prostate cancer Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 206010037549 Purpura Diseases 0.000 description 2
• 241001672981 Purpura Species 0.000 description 2
• 108010039491 Ricin Proteins 0.000 description 2
• 206010039491 Sarcoma Diseases 0.000 description 2
• 206010039710 Scleroderma Diseases 0.000 description 2
• 102000003800 Selectins Human genes 0.000 description 2
• 108090000184 Selectins Proteins 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 108091008874 T cell receptors Proteins 0.000 description 2
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
• 101150006914 TRP1 gene Proteins 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• 108010022394 Threonine synthase Proteins 0.000 description 2
• 102000011923 Thyrotropin Human genes 0.000 description 2
• 108010061174 Thyrotropin Proteins 0.000 description 2
• 108010009583 Transforming Growth Factors Proteins 0.000 description 2
• 102000009618 Transforming Growth Factors Human genes 0.000 description 2
• 239000007983 Tris buffer Substances 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 229940122803 Vinca alkaloid Drugs 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 238000011360 adjunctive therapy Methods 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 229940009456 adriamycin Drugs 0.000 description 2
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 125000000129 anionic group Chemical group 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 235000009582 asparagine Nutrition 0.000 description 2
• 229960001230 asparagine Drugs 0.000 description 2
• 235000003704 aspartic acid Nutrition 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
• 229960002685 biotin Drugs 0.000 description 2
• 235000020958 biotin Nutrition 0.000 description 2
• 239000011616 biotin Substances 0.000 description 2
• 230000017531 blood circulation Effects 0.000 description 2
• 238000004820 blood count Methods 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 231100000366 bone marrow toxicity Toxicity 0.000 description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
• 229930195731 calicheamicin Natural products 0.000 description 2
• 229940112129 campath Drugs 0.000 description 2
• 235000014633 carbohydrates Nutrition 0.000 description 2
• 229910052799 carbon Inorganic materials 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 229960005243 carmustine Drugs 0.000 description 2
• NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
• 230000004087 circulation Effects 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 230000024203 complement activation Effects 0.000 description 2
• 239000002299 complementary DNA Substances 0.000 description 2
• 239000000356 contaminant Substances 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 230000001085 cytostatic effect Effects 0.000 description 2
• 230000003013 cytotoxicity Effects 0.000 description 2
• 231100000135 cytotoxicity Toxicity 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 230000001627 detrimental effect Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000002612 dispersion medium Substances 0.000 description 2
• 238000009826 distribution Methods 0.000 description 2
• 150000002019 disulfides Chemical class 0.000 description 2
• 230000009977 dual effect Effects 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 231100000321 erythema Toxicity 0.000 description 2
• 229940105423 erythropoietin Drugs 0.000 description 2
• 210000003527 eukaryotic cell Anatomy 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 238000002710 external beam radiation therapy Methods 0.000 description 2
• 239000000284 extract Substances 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 229940028334 follicle stimulating hormone Drugs 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 238000010353 genetic engineering Methods 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 208000005017 glioblastoma Diseases 0.000 description 2
• 235000013922 glutamic acid Nutrition 0.000 description 2
• 239000004220 glutamic acid Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 230000002949 hemolytic effect Effects 0.000 description 2
• 239000003667 hormone antagonist Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 239000000367 immunologic factor Substances 0.000 description 2
• 238000001114 immunoprecipitation Methods 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 210000003000 inclusion body Anatomy 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 238000007917 intracranial administration Methods 0.000 description 2
• 239000007927 intramuscular injection Substances 0.000 description 2
• 238000010255 intramuscular injection Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000005342 ion exchange Methods 0.000 description 2
• 150000002500 ions Chemical class 0.000 description 2
• 238000010829 isocratic elution Methods 0.000 description 2
• 150000002540 isothiocyanates Chemical class 0.000 description 2
• 238000005304 joining Methods 0.000 description 2
• 206010023332 keratitis Diseases 0.000 description 2
• 238000009533 lab test Methods 0.000 description 2
• 108020001756 ligand binding domains Proteins 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 229940040129 luteinizing hormone Drugs 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
• 229960001924 melphalan Drugs 0.000 description 2
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 239000003607 modifier Substances 0.000 description 2
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
• 201000005962 mycosis fungoides Diseases 0.000 description 2
• 230000017074 necrotic cell death Effects 0.000 description 2
• 239000003900 neurotrophic factor Substances 0.000 description 2
• 239000000199 parathyroid hormone Substances 0.000 description 2
• 229960001319 parathyroid hormone Drugs 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 201000001976 pemphigus vulgaris Diseases 0.000 description 2
• 230000003285 pharmacodynamic effect Effects 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• 238000001742 protein purification Methods 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 230000000637 radiosensitizating effect Effects 0.000 description 2
• 239000000376 reactant Substances 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 230000010076 replication Effects 0.000 description 2
• 206010039073 rheumatoid arthritis Diseases 0.000 description 2
• 238000002702 ribosome display Methods 0.000 description 2
• 102200106299 rs1057519982 Human genes 0.000 description 2
• 238000009118 salvage therapy Methods 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
• 210000000952 spleen Anatomy 0.000 description 2
• 210000004989 spleen cell Anatomy 0.000 description 2
• 230000000707 stereoselective effect Effects 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
• 125000001424 substituent group Chemical group 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 206010043207 temporal arteritis Diseases 0.000 description 2
• 238000012360 testing method Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 238000005809 transesterification reaction Methods 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 2
• 229960004560 triaziquone Drugs 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 229960005356 urokinase Drugs 0.000 description 2
• 239000012646 vaccine adjuvant Substances 0.000 description 2
• 229940124931 vaccine adjuvant Drugs 0.000 description 2
• 229910052720 vanadium Inorganic materials 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
• MCEHFIXEKNKSRW-LBPRGKRZSA-N (2s)-2-[[3,5-dichloro-4-[(2,4-diaminopteridin-6-yl)methyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=C(Cl)C=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1Cl MCEHFIXEKNKSRW-LBPRGKRZSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
• 101150028074 2 gene Proteins 0.000 description 1
• OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
• FZDFGHZZPBUTGP-UHFFFAOYSA-N 2-[[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical class OC(=O)CN(CC(O)=O)C(C)CN(CC(O)=O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 FZDFGHZZPBUTGP-UHFFFAOYSA-N 0.000 description 1
• 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
• 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
• AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical class NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 1
• 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
• XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
• 108010066676 Abrin Proteins 0.000 description 1
• 101100295756 Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81) omp38 gene Proteins 0.000 description 1
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 206010001881 Alveolar proteinosis Diseases 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 244000303258 Annona diversifolia Species 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 108010032595 Antibody Binding Sites Proteins 0.000 description 1
• 208000032467 Aplastic anaemia Diseases 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 208000033241 Autosomal dominant hyper-IgE syndrome Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
• 241001112741 Bacillaceae Species 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
• 102000013585 Bombesin Human genes 0.000 description 1
• 108010051479 Bombesin Proteins 0.000 description 1
• 241000701822 Bovine papillomavirus Species 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 241000219193 Brassicaceae Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
• 208000033386 Buerger disease Diseases 0.000 description 1
• 208000023611 Burkitt leukaemia Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 239000012619 Butyl Sepharose® Substances 0.000 description 1
• 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
• 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
• 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
• 101710155855 C-C motif chemokine 4 Proteins 0.000 description 1
• 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
• 201000002829 CREST Syndrome Diseases 0.000 description 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
• 229940045513 CTLA4 antagonist Drugs 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• 101100228196 Caenorhabditis elegans gly-4 gene Proteins 0.000 description 1
• 102000055006 Calcitonin Human genes 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 241000282836 Camelus dromedarius Species 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
• 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
• 241000251730 Chondrichthyes Species 0.000 description 1
• 102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
• 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
• 229910020366 ClO 4 Inorganic materials 0.000 description 1
• 238000005821 Claisen rearrangement reaction Methods 0.000 description 1
• 102100022641 Coagulation factor IX Human genes 0.000 description 1
• 102100023804 Coagulation factor VII Human genes 0.000 description 1
• 241000272201 Columbiformes Species 0.000 description 1
• 102000016917 Complement C1 Human genes 0.000 description 1
• 108010028774 Complement C1 Proteins 0.000 description 1
• 102000014447 Complement C1q Human genes 0.000 description 1
• 108010078043 Complement C1q Proteins 0.000 description 1
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 206010063057 Cystitis noninfective Diseases 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
• GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 102000010170 Death domains Human genes 0.000 description 1
• 108050001718 Death domains Proteins 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 208000021866 Dressler syndrome Diseases 0.000 description 1
• 229930193152 Dynemicin Natural products 0.000 description 1
• 108010024212 E-Selectin Proteins 0.000 description 1
• 102100023471 E-selectin Human genes 0.000 description 1
• 201000004315 EAST syndrome Diseases 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 241000588921 Enterobacteriaceae Species 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 206010053776 Eosinophilic cellulitis Diseases 0.000 description 1
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 1
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 description 1
• 108090000371 Esterases Proteins 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 108050001049 Extracellular proteins Proteins 0.000 description 1
• 108010076282 Factor IX Proteins 0.000 description 1
• 108010014172 Factor V Proteins 0.000 description 1
• 108010023321 Factor VII Proteins 0.000 description 1
• 108010054218 Factor VIII Proteins 0.000 description 1
• 102000001690 Factor VIII Human genes 0.000 description 1
• 108010014173 Factor X Proteins 0.000 description 1
• 108010074864 Factor XI Proteins 0.000 description 1
• 108010080865 Factor XII Proteins 0.000 description 1
• 102000000429 Factor XII Human genes 0.000 description 1
• 108010071289 Factor XIII Proteins 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108010049003 Fibrinogen Proteins 0.000 description 1
• 102000008946 Fibrinogen Human genes 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
• 101150048336 Flt1 gene Proteins 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
• 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 102400000321 Glucagon Human genes 0.000 description 1
• 108060003199 Glucagon Proteins 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 206010018690 Granulocytosis Diseases 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000003807 Graves Disease Diseases 0.000 description 1
• 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
• 108091008603 HGF receptors Proteins 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 208000037357 HIV infectious disease Diseases 0.000 description 1
• 241000606768 Haemophilus influenzae Species 0.000 description 1
• 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
• 101100028493 Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 / VKM B-1768 / DS2) pan2 gene Proteins 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 229920002971 Heparan sulfate Polymers 0.000 description 1
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 1
• 206010019860 Hereditary angioedema Diseases 0.000 description 1
• 208000009889 Herpes Simplex Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
• 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
• 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
• 101000642195 Homo sapiens Protein turtle homolog A Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 206010073257 Idiopathic angioedema Diseases 0.000 description 1
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
• 108010073816 IgE Receptors Proteins 0.000 description 1
• 102000009438 IgE Receptors Human genes 0.000 description 1
• 102000009490 IgG Receptors Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
• 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
• 102100025323 Integrin alpha-1 Human genes 0.000 description 1
• 102100022339 Integrin alpha-L Human genes 0.000 description 1
• 108010041341 Integrin alpha1 Proteins 0.000 description 1
• 108010055795 Integrin alpha1beta1 Proteins 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 description 1
• 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000003996 Interferon-beta Human genes 0.000 description 1
• 108090000467 Interferon-beta Proteins 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102000000589 Interleukin-1 Human genes 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108090000177 Interleukin-11 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 102000004889 Interleukin-6 Human genes 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 208000009388 Job Syndrome Diseases 0.000 description 1
• 208000003456 Juvenile Arthritis Diseases 0.000 description 1
• 208000012528 Juvenile dermatomyositis Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• 101150088608 Kdr gene Proteins 0.000 description 1
• 102100038609 Lactoperoxidase Human genes 0.000 description 1
• 108010023244 Lactoperoxidase Proteins 0.000 description 1
• 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 108090001030 Lipoproteins Proteins 0.000 description 1
• 102000004895 Lipoproteins Human genes 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
• 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
• 108010091221 Lymphotoxin beta Receptor Proteins 0.000 description 1
• 102000018170 Lymphotoxin beta Receptor Human genes 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
• 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
• 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 108010006035 Metalloproteases Proteins 0.000 description 1
• 102000005741 Metalloproteases Human genes 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• 206010059282 Metastases to central nervous system Diseases 0.000 description 1
• 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 description 1
• 102100026632 Mimecan Human genes 0.000 description 1
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
• 206010027910 Mononeuritis Diseases 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 108010008707 Mucin-1 Proteins 0.000 description 1
• 102100034256 Mucin-1 Human genes 0.000 description 1
• 206010028080 Mucocutaneous candidiasis Diseases 0.000 description 1
• 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 1
• 101710139349 Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 1
• 101100425758 Mus musculus Tnfrsf1b gene Proteins 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• WTBIAPVQQBCLFP-UHFFFAOYSA-N N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O Chemical compound N.N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O WTBIAPVQQBCLFP-UHFFFAOYSA-N 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 108090000095 Neurotrophin-6 Proteins 0.000 description 1
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
• 101800002327 Osteoinductive factor Proteins 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 206010068786 Overlap syndrome Diseases 0.000 description 1
• XGJQGEQHHDEVEW-UHFFFAOYSA-N P(=O)(=O)S(=O)(=O)O Chemical compound P(=O)(=O)S(=O)(=O)O XGJQGEQHHDEVEW-UHFFFAOYSA-N 0.000 description 1
• 108010035766 P-Selectin Proteins 0.000 description 1
• 102100023472 P-selectin Human genes 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 108700034306 PROMACE-CytaBOM protocol Proteins 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000002193 Pain Diseases 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 206010034498 Pericarditis uraemic Diseases 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 241000235648 Pichia Species 0.000 description 1
• 108010003044 Placental Lactogen Proteins 0.000 description 1
• 239000000381 Placental Lactogen Substances 0.000 description 1
• 102000013566 Plasminogen Human genes 0.000 description 1
• 108010051456 Plasminogen Proteins 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• HRHKSTOGXBBQCB-UHFFFAOYSA-N Porfiromycine Chemical compound O=C1C(N)=C(C)C(=O)C2=C1C(COC(N)=O)C1(OC)C3N(C)C3CN12 HRHKSTOGXBBQCB-UHFFFAOYSA-N 0.000 description 1
• 206010036303 Post streptococcal glomerulonephritis Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 108010076181 Proinsulin Proteins 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 102100033219 Protein turtle homolog A Human genes 0.000 description 1
• 108010094028 Prothrombin Proteins 0.000 description 1
• 102100027378 Prothrombin Human genes 0.000 description 1
• 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
• 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 108091093078 Pyrimidine dimer Proteins 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 208000033464 Reiter syndrome Diseases 0.000 description 1
• 108090000103 Relaxin Proteins 0.000 description 1
• 102000003743 Relaxin Human genes 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 102100028255 Renin Human genes 0.000 description 1
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 238000003514 Retro-Michael reaction Methods 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 206010039085 Rhinitis allergic Diseases 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 241000235343 Saccharomycetales Species 0.000 description 1
• 241000607142 Salmonella Species 0.000 description 1
• 206010039705 Scleritis Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010058556 Serositis Diseases 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• 239000005708 Sodium hypochlorite Substances 0.000 description 1
• 102100022831 Somatoliberin Human genes 0.000 description 1
• 101710142969 Somatoliberin Proteins 0.000 description 1
• 102000004584 Somatomedin Receptors Human genes 0.000 description 1
• 108010017622 Somatomedin Receptors Proteins 0.000 description 1
• 102000013275 Somatomedins Human genes 0.000 description 1
• 229910000831 Steel Inorganic materials 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 241000194017 Streptococcus Species 0.000 description 1
• ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
• 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
• 206010043189 Telangiectasia Diseases 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 206010043376 Tetanus Diseases 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 101150009046 Tnfrsf1a gene Proteins 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 206010052568 Urticaria chronic Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 108091008605 VEGF receptors Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 206010046914 Vaginal infection Diseases 0.000 description 1
• 201000008100 Vaginitis Diseases 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 206010047124 Vasculitis necrotising Diseases 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 241000863480 Vinca Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 208000008526 Wells syndrome Diseases 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
• MNOGBRROKHFONU-CJUKMMNNSA-N ac1l2wzw Chemical compound C1N2C(C(C(C)=C(NCCOP(O)(O)=O)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 MNOGBRROKHFONU-CJUKMMNNSA-N 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• ZMPZNCDIFIQVJZ-UHFFFAOYSA-N acetic acid;n'-[2-(cyclohexylamino)ethyl]ethane-1,2-diamine Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O.NCCNCCNC1CCCCC1 ZMPZNCDIFIQVJZ-UHFFFAOYSA-N 0.000 description 1
• 108010090455 acetyl-E VEALEKK VAALESK VQALEKK VEALEHG-amide Proteins 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 201000004484 acute conjunctivitis Diseases 0.000 description 1
• 201000005661 acute cystitis Diseases 0.000 description 1
• 208000012873 acute gastroenteritis Diseases 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 201000005638 acute proliferative glomerulonephritis Diseases 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000003463 adsorbent Substances 0.000 description 1
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 108010035879 albumin-bilirubin complex Proteins 0.000 description 1
• 238000005575 aldol reaction Methods 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• 208000026935 allergic disease Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000000961 alloantigen Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 150000001412 amines Chemical group 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 230000002052 anaphylactic effect Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 239000003098 androgen Substances 0.000 description 1
• 229940030486 androgens Drugs 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 229940045799 anthracyclines and related substance Drugs 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 230000003432 anti-folate effect Effects 0.000 description 1
• 230000003602 anti-herpes Effects 0.000 description 1
• 230000036436 anti-hiv Effects 0.000 description 1
• 230000003388 anti-hormonal effect Effects 0.000 description 1
• 230000001064 anti-interferon Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000000729 antidote Substances 0.000 description 1
• 229940127074 antifolate Drugs 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 230000009876 antimalignant effect Effects 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 101150042295 arfA gene Proteins 0.000 description 1
• 239000003886 aromatase inhibitor Substances 0.000 description 1
• 229940046844 aromatase inhibitors Drugs 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000000429 assembly Methods 0.000 description 1
• 230000000712 assembly Effects 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 201000004995 autoimmune glomerulonephritis Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 230000001651 autotrophic effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 238000010364 biochemical engineering Methods 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 239000003139 biocide Substances 0.000 description 1
• 238000001815 biotherapy Methods 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 229940019700 blood coagulation factors Drugs 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• PKOMXLRKGNITKG-UHFFFAOYSA-L calcium;hydroxy(methyl)arsinate Chemical compound [Ca+2].C[As](O)([O-])=O.C[As](O)([O-])=O PKOMXLRKGNITKG-UHFFFAOYSA-L 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
• 229930188550 carminomycin Natural products 0.000 description 1
• XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 229950001725 carubicin Drugs 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 239000003518 caustics Substances 0.000 description 1
• 238000012832 cell culture technique Methods 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
• 230000002032 cellular defenses Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000000919 ceramic Substances 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• 230000003399 chemotactic effect Effects 0.000 description 1
• 239000005482 chemotactic factor Substances 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 201000010415 childhood type dermatomyositis Diseases 0.000 description 1
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 201000001352 cholecystitis Diseases 0.000 description 1
• 238000011098 chromatofocusing Methods 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 201000005547 chronic conjunctivitis Diseases 0.000 description 1
• 201000003139 chronic cystitis Diseases 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 201000006778 chronic monocytic leukemia Diseases 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 208000024376 chronic urticaria Diseases 0.000 description 1
• VYVRIXWNTVOIRD-UHFFFAOYSA-N ciguatoxin Natural products O1C(C(C(C)C2OC3CC(C)CC4OC5(C)C(O)CC6OC7C=CC8OC9CC%10C(C(C%11OC(C=CCC%11O%10)C=CC(O)CO)O)OC9C=CC8OC7CC=CCC6OC5CC4OC3CC2O2)O)C2C(C)C(C)C21CC(O)CO2 VYVRIXWNTVOIRD-UHFFFAOYSA-N 0.000 description 1
• 238000003759 clinical diagnosis Methods 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 229920006026 co-polymeric resin Polymers 0.000 description 1
• 239000003245 coal Substances 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 206010009869 cold urticaria Diseases 0.000 description 1
• 206010009887 colitis Diseases 0.000 description 1
• 201000010897 colon adenocarcinoma Diseases 0.000 description 1
• 230000004154 complement system Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 201000003278 cryoglobulinemia Diseases 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 1
• IMBXRZKCLVBLBH-OGYJWPHRSA-N cvp protocol Chemical compound ClCCN(CCCl)P1(=O)NCCCO1.O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C([C@H](C[C@]1(C(=O)OC)C=2C(=C3C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)=CC=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 IMBXRZKCLVBLBH-OGYJWPHRSA-N 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 239000007857 degradation product Substances 0.000 description 1
• 238000005695 dehalogenation reaction Methods 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 238000002405 diagnostic procedure Methods 0.000 description 1
• 235000015872 dietary supplement Nutrition 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• HQWKKEIVHQXCPI-UHFFFAOYSA-L disodium;phthalate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C([O-])=O HQWKKEIVHQXCPI-UHFFFAOYSA-L 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000011143 downstream manufacturing Methods 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000005611 electricity Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 238000005538 encapsulation Methods 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 210000003989 endothelium vascular Anatomy 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
• 108010002591 epsilon receptor Proteins 0.000 description 1
• 239000006167 equilibration buffer Substances 0.000 description 1
• LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 229960000752 etoposide phosphate Drugs 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 231100000776 exotoxin Toxicity 0.000 description 1
• 239000002095 exotoxin Substances 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 229960004222 factor ix Drugs 0.000 description 1
• 229940012413 factor vii Drugs 0.000 description 1
• 229960000301 factor viii Drugs 0.000 description 1
• 229940012426 factor x Drugs 0.000 description 1
• 229940012444 factor xiii Drugs 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 238000000855 fermentation Methods 0.000 description 1
• 230000004151 fermentation Effects 0.000 description 1
• 229940012952 fibrinogen Drugs 0.000 description 1
• 230000003480 fibrinolytic effect Effects 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
• 229960004413 flucytosine Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 238000011010 flushing procedure Methods 0.000 description 1
• 239000004052 folic acid antagonist Substances 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 238000013467 fragmentation Methods 0.000 description 1
• 238000006062 fragmentation reaction Methods 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
• 238000003500 gene array Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
• 229960004666 glucagon Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229960001031 glucose Drugs 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 108010033706 glycylserine Proteins 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 210000003714 granulocyte Anatomy 0.000 description 1
• 201000008326 granulomatous myositis Diseases 0.000 description 1
• 239000000122 growth hormone Substances 0.000 description 1
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
• 229940047650 haemophilus influenzae Drugs 0.000 description 1
• 235000015220 hamburgers Nutrition 0.000 description 1
• 229910001385 heavy metal Inorganic materials 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• 208000021760 high fever Diseases 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 239000012510 hollow fiber Substances 0.000 description 1
• 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
• 230000008348 humoral response Effects 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
• 230000033444 hydroxylation Effects 0.000 description 1
• 238000005805 hydroxylation reaction Methods 0.000 description 1
• 229960002899 hydroxyprogesterone Drugs 0.000 description 1
• 208000014796 hyper-IgE recurrent infection syndrome 1 Diseases 0.000 description 1
• 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000005931 immune cell recruitment Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 230000001024 immunotherapeutic effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 208000014674 injury Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 238000012432 intermediate storage Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 230000026045 iodination Effects 0.000 description 1
• 238000006192 iodination reaction Methods 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 230000001678 irradiating effect Effects 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 201000010666 keratoconjunctivitis Diseases 0.000 description 1
• 201000000062 kidney sarcoma Diseases 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 229940057428 lactoperoxidase Drugs 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940039781 leptin Drugs 0.000 description 1
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 235000015073 liquid stocks Nutrition 0.000 description 1
• 238000011068 loading method Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 230000000527 lymphocytic effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000000873 masking effect Effects 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 description 1
• 229960001810 meprednisone Drugs 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
• 239000011325 microbead Substances 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 230000009149 molecular binding Effects 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 208000013734 mononeuritis simplex Diseases 0.000 description 1
• 201000005518 mononeuropathy Diseases 0.000 description 1
• 230000000921 morphogenic effect Effects 0.000 description 1
• 230000001459 mortal effect Effects 0.000 description 1
• 102000051367 mu Opioid Receptors Human genes 0.000 description 1
• 201000011201 multicentric reticulohistiocytosis Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• UGAHKAYVILJXGK-UHFFFAOYSA-N n-(2-aminoethyl)-n'-[2-(propylamino)ethyl]propane-1,3-diamine Chemical compound CCCNCCNCCCNCCN UGAHKAYVILJXGK-UHFFFAOYSA-N 0.000 description 1
• 201000009240 nasopharyngitis Diseases 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 201000001119 neuropathy Diseases 0.000 description 1
• 230000007823 neuropathy Effects 0.000 description 1
• 230000000508 neurotrophic effect Effects 0.000 description 1
• 229940032018 neurotrophin 3 Drugs 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical class NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 239000002751 oligonucleotide probe Substances 0.000 description 1
• 238000002515 oligonucleotide synthesis Methods 0.000 description 1
• 150000002482 oligosaccharides Polymers 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 101150087557 omcB gene Proteins 0.000 description 1
• 101150115693 ompA gene Proteins 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 230000014207 opsonization Effects 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229940029358 orthoclone okt3 Drugs 0.000 description 1
• 201000008482 osteoarthritis Diseases 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 101150081585 panB gene Proteins 0.000 description 1
• 101150012634 panT gene Proteins 0.000 description 1
• 201000002528 pancreatic cancer Diseases 0.000 description 1
• 208000008443 pancreatic carcinoma Diseases 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 208000000793 papillary cystadenoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000008010 parenteral excipient Substances 0.000 description 1
• 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 1
• 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 101150040383 pel2 gene Proteins 0.000 description 1
• 101150050446 pelB gene Proteins 0.000 description 1
• 230000000149 penetrating effect Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000003516 pericardium Anatomy 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 101150009573 phoA gene Proteins 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 239000007981 phosphate-citrate buffer Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000003169 placental effect Effects 0.000 description 1
• 229940012957 plasmin Drugs 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 208000008423 pleurisy Diseases 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229960001237 podophyllotoxin Drugs 0.000 description 1
• YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
• 239000003600 podophyllotoxin derivative Substances 0.000 description 1
• 201000006292 polyarteritis nodosa Diseases 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 208000019629 polyneuritis Diseases 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229950008882 polysorbate Drugs 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• WINGFJQHCRYKRB-UHFFFAOYSA-L potassium;sodium;diiodide Chemical compound [Na+].[K+].[I-].[I-] WINGFJQHCRYKRB-UHFFFAOYSA-L 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 108010087851 prorelaxin Proteins 0.000 description 1
• 210000005267 prostate cell Anatomy 0.000 description 1
• 239000012460 protein solution Substances 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 231100000654 protein toxin Toxicity 0.000 description 1
• 229940039716 prothrombin Drugs 0.000 description 1
• 210000001938 protoplast Anatomy 0.000 description 1
• CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 239000013014 purified material Substances 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 229940051022 radioimmunoconjugate Drugs 0.000 description 1
• 208000002574 reactive arthritis Diseases 0.000 description 1
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 238000006479 redox reaction Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 208000009169 relapsing polychondritis Diseases 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 229940107685 reopro Drugs 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 238000005185 salting out Methods 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 description 1
• RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 description 1
• 208000010157 sclerosing cholangitis Diseases 0.000 description 1
• 208000037921 secondary disease Diseases 0.000 description 1
• 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
• 238000001338 self-assembly Methods 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000010898 silica gel chromatography Methods 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 229940115586 simulect Drugs 0.000 description 1
• 201000009890 sinusitis Diseases 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 235000017281 sodium acetate Nutrition 0.000 description 1
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
• 229960000553 somatostatin Drugs 0.000 description 1
• 229960004532 somatropin Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000012430 stability testing Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000010959 steel Substances 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 229940036185 synagis Drugs 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 229910052713 technetium Inorganic materials 0.000 description 1
• 229940056501 technetium 99m Drugs 0.000 description 1
• GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• 208000009056 telangiectasis Diseases 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• UDEJEOLNSNYQSX-UHFFFAOYSA-J tetrasodium;2,4,6,8-tetraoxido-1,3,5,7,2$l^{5},4$l^{5},6$l^{5},8$l^{5}-tetraoxatetraphosphocane 2,4,6,8-tetraoxide Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)O1 UDEJEOLNSNYQSX-UHFFFAOYSA-J 0.000 description 1
• CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
• 229950010357 tetrodotoxin Drugs 0.000 description 1
• CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 229940126585 therapeutic drug Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
• 206010043778 thyroiditis Diseases 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
• 229960000187 tissue plasminogen activator Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000001296 transplacental effect Effects 0.000 description 1
• 238000002054 transplantation Methods 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
• 101150025395 trkA gene Proteins 0.000 description 1
• 101150113435 trkA1 gene Proteins 0.000 description 1
• 102000047459 trkC Receptor Human genes 0.000 description 1
• 108010064892 trkC Receptor Proteins 0.000 description 1
• 230000005747 tumor angiogenesis Effects 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
• 238000000108 ultra-filtration Methods 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 208000000143 urethritis Diseases 0.000 description 1
• 210000002700 urine Anatomy 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 210000002845 virion Anatomy 0.000 description 1
• 108010047303 von Willebrand Factor Proteins 0.000 description 1
• 102100036537 von Willebrand factor Human genes 0.000 description 1
• 229960001134 von willebrand factor Drugs 0.000 description 1
• 239000002699 waste material Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 150000003952 β-lactams Chemical class 0.000 description 1
• 108020001612 μ-opioid receptors Proteins 0.000 description 1